Cathay Biotech (SH:688065) Shenwan Hongyuan Securities·2025-04-30 12:42Investment Rating - The report maintains an "Outperform" rating for the company [2] Core Views - The company's Q1 2025 performance met expectations, with total revenue of 776 million yuan, a year-on-year increase of 13% and a quarter-on-quarter increase of 4%. The net profit attributable to the parent company was 137 million yuan, reflecting a year-on-year growth of 30% [6][7] - The long-chain dicarboxylic acid business is experiencing steady growth, particularly with the ramp-up of sebacic acid, which has enhanced profitability. The company has increased sales efforts and is expanding its market share in new products [6] - Significant progress has been made in promoting bio-based polyamide modified and continuous fiber composite materials, with commercial orders expected to materialize [6] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 3,539 million yuan, with a year-on-year growth rate of 19.6%. The net profit attributable to the parent company is forecasted to be 648 million yuan, representing a growth rate of 32.4% [6][7] - The gross profit margin for Q1 2025 was 33.63%, showing an increase of 4.95 percentage points year-on-year and 5.22 percentage points quarter-on-quarter [6] - The company’s return on equity (ROE) is projected to improve from 0.8% in Q1 2025 to 5.4% by 2027 [6]